On November 13, 2020 AskAt Inc. (AskAt) reported that it received a Notice of Allowance dated November 3, 2020 from the United States Patent and Trademark Office (USPTO) in connection with Application No.16/803,163, a use patent for AskAt’s EP4 antagonist (grapiprant, AAT-007) in the treatment of melanoma, leukemia, lymphoma, and liver cancer (Press release, AskAt, NOV 13, 2020, View Source [SID1234570816]). AskAt has previously received an allowance for the use of grapiprant in the treatment of epithelial cancer and several cancer types.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ikena Oncology, Inc (formally Kyn Therapeutics, Inc. which licensed worldwide rights to AskAt’s EP4 antagonists except in China) and Ningbo NewBay Pharmaceutical Co. Ltd. (a subsidiary of Ningbo Tai Kang Medical Technology Co. Ltd., which licensed AskAt’s EP4 antagonists for cancer use in China) are currently conducting clinical studies of grapiprant (IK-007/RMX-1002) in the U.S. and China, respectively.